Uniplan Investment Counsel’s Akoya BioSciences AKYA Stock Holding History

Uniplan Investment Counsel’s Portfolio AKYA Stock Details AKYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-699,837	Closed	-$3.28M	–	118
2024 Q1	$3.28M	Buy	699,837 +26,314	+4%	+$137K	0.26%	80
2023 Q4	$3.42M	Buy	673,523 +118,963	+21%	+$494K	0.25%	81
2023 Q3	$2.58M	Buy	554,560 +11,344	+2%	+$65.2K	0.2%	94
2023 Q2	$4.01M	Buy	543,216 +78,012	+17%	+$521K	0.29%	73
2023 Q1	$3.81M	Buy	465,204 +64,848	+16%	+$677K	0.27%	75
2022 Q4	$3.83M	Buy	400,356 +232,647	+139%	+$2.86M	0.27%	80
2022 Q3	$1.97M	Buy	+167,709	New	+$2.21M	0.15%	107

Other funds holding AKYA

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Uniplan Investment Counsel's AKYA Position: Q2 2024 in Review

Uniplan Investment Counsel sold out of Akoya BioSciences (AKYA) in Q2 2024, closing a stake of 699,837 shares — an estimated $3.28M sold.

Uniplan Investment Counsel first reported a position in AKYA in Q3 2022 and held it in 7 quarters. The position peaked at $4.01M in Q2 2023. 59 funds tracked by Wall St. Rank hold AKYA as of Q2 2024.

Uniplan Investment Counsel reported no remaining Akoya BioSciences position as of Q2 2024 after selling out during the quarter.
Uniplan Investment Counsel sold 699,837 Akoya BioSciences shares in Q2 2024, an estimated $3.28M.
Uniplan Investment Counsel first reported a position in Akoya BioSciences in Q3 2022 and held it in 7 quarters.
Uniplan Investment Counsel's Akoya BioSciences position peaked at $4.01M in Q2 2023.
59 funds tracked by Wall St. Rank held Akoya BioSciences as of Q2 2024.

Based on Uniplan Investment Counsel's 13F filing for Q2 2024, filed 14 Aug 2024.